Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | BCL6 | P41182 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.46 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829781 | 0.94 | RAB9A (0.65) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL4836573 | 0.90 | BCL6 (0.68) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL4829511 | 0.88 | MAPT (0.75) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL4832399 | 0.88 | RAB9A (0.53) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL4839296 | 0.86 | BCL6 (0.61) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL4839119 | 0.86 | BCL6 (0.61) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL14268318 | 0.86 | BCL6 (0.63) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL4835764 | 0.86 | MAPT (0.69) | MAPTGAARAB9ANPC1BCL6 | |
| SCHEMBL13326019 | 0.85 | RAB9A (0.66) | MAPTRAB9ABCL6MEN1LMNA | |
| SCHEMBL4832464 | 0.85 | MAPT (0.75) | MAPTGAARAB9ANPC1BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | claimed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | claimed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | claimed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
| WO-2004026844-A9 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-11-11 | — | — | US | disclosed |
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
| US-20040209880-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
| US-20040209881-A1 | e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MAPT 3539/4885GAA 852/4885RAB9A 4709/4885 |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | MAPT 2787/4885GAA 1053/4885RAB9A 4747/4885 |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MAPT 3539/4885GAA 852/4885RAB9A 4709/4885 |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MAPT 3539/4885GAA 852/4885RAB9A 4709/4885 |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | MAPT 3475/4885GAA 1099/4885RAB9A 4800/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | MAPT 3475/4885GAA 1099/4885RAB9A 4800/4885 |
| US-20040209881-A1 | e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme | ENGASE, LIPG, GPI | MAPT 4022/4885GAA 44/4885RAB9A 4715/4885 |
| US-20040209880-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MAPT 3539/4885GAA 852/4885RAB9A 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.